Share Price:

APNASPENAspen Pharmacare Hldgs10393113 (1.10%)

Aspen building momentum in Commercial Pharmaceuticals and Manufacturing strategy modified

Stephen Saad, Aspen Group Chief Executive

Aspen Pharmacare Holdings has reported financial results for the year ended 30 June 2025, with strong momentum in Commercial Pharmaceuticals and a modified Manufacturing strategy.

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.